As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|July 31, 2017
Nephrology and Urology Market Growth Predictions Drive $57 Billion Investment
Advertisement
GlobalData, a provider of business information and analytics, released its latest report on the Nephrology and Urology devices market. The report highlights that the burst in diabetes and hypertension combined with aging populations is driving investment to meet patient needs. Leading companies in the field-primarily from Europe and North America-have invested more than $42 billion in mergers and acquisitions and almost $15 billion in capital raisings over the last three years.
The incontinence devices category is expected to show the quickest growth rate with a compound annual growth rate (CAGR) of 4.7% between 2016 and 2023, closely followed by the renal dialysis equipment category with a CAGR of 4.4% for the same period.
In 2016, renal dialysis equipment accounted for over 55% of the market value-at over $17 billion-and is expected to rise to over $26 billion by 2026.
According to GlobalData’s researchers, almost 60% of renal dialysis patient growth will be driven by the emerging markets of China, Brazil, and India-which will account for 48% of the dialysis population by 2026.
Advertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5